C3 glomerulopathy in children: experience at a resource-limited center
Open Access
- 28 November 2024
- journal article
- Published by Korean Pediatric Society in Clinical and Experimental Pediatrics
- Vol. 68 (4) , 311-318
Abstract
In children, C3 glomerulopathy (C3G) is a heterogeneous disease characterized by diverse clinicopathological profiles and kidney outcomes. However, diagnostic work-up in resource-limited settings is challenging because of the unavailability of complement assays and limited access to electron microscopy or genetic testing. This study aimed to describe the clinicopathological features and response to immunosuppression and evaluate renal outcomes among children with C3G in a resource-limited setting. This retrospective cohort study involved a review of the hospital records of 46 children (2013-2021) diagnosed with C3G on kidney biopsy. Their clinical, laboratory, treatment, and outcome details at onset and follow-up were noted. The mean (SD) age was 9 (4) years. The common presentation was acute nephritis (27 [58.6%]), while one in five (19.5%) presented with rapidly progressive glomerulonephritis. Focal-crescentic glomerulonephritis (14 [30.4%]) was the common histological pattern. Electron microscopy was performed in 22 (47.8%), of which 17 were C3 glomerulonephritis (C3GN) and four were dense deposit disease (DDD). None of the patients underwent complement assay or genetic testing. Almost two-thirds (63%) received empirical immunosuppressive therapy, most commonly steroids. Of the 31/46 who completed follow-up (median [IQR] duration, 11.5 [6-24] months), six (19.4%) demonstrated complete kidney recovery, while the other 25 (80.7%) had kidney sequelae; of them, five (16.1%) progressed to end-stage kidney disease and two (4.3%) died by the last follow-up. Pediatric C3G has a variable clinicopathological spectrum, while DDD is less common. Most patients present with glomerulonephritis and significant morbidities. The lack of genetic and C3Nephritic factor testing is a barrier to the comprehensive phenotyping and management of C3G in resource-limited settings.Keywords
This publication has 25 references indexed in Scilit:
- Testing the Activity of Complement Convertases in Serum/Plasma for Diagnosis of C4NeF-Mediated C3 GlomerulonephritisJournal of Clinical Immunology, 2016
- AJKD Atlas of Renal Pathology: Glomerulonephritis With Dominant C3American Journal of Kidney Diseases, 2015
- Eculizumab in Pediatric Dense Deposit DiseaseClinical Journal of the American Society of Nephrology, 2015
- AJKD Atlas of Renal Pathology: Membranoproliferative GlomerulonephritisAmerican Journal of Kidney Diseases, 2015
- Clinico-pathologic spectrum of C3 glomerulopathy-an Indian experienceDiagnostic Pathology, 2015
- C3 GlomerulopathyClinical Journal of the American Society of Nephrology, 2014
- Acquired and genetic complement abnormalities play a critical role in dense deposit disease and other C3 glomerulopathiesKidney International, 2012
- C3 glomerulonephritis: clinicopathological findings, complement abnormalities, glomerular proteomic profile, treatment, and follow-upKidney International, 2012
- Eculizumab for Dense Deposit Disease and C3 GlomerulonephritisClinical Journal of the American Society of Nephrology, 2012
- Histopathologic Classification of ANCA-Associated GlomerulonephritisJournal of the American Society of Nephrology, 2010